Aclaris Therapeutics, Inc.

ACRS · NASDAQ

Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.

Follow Add to Watchlist Ask Question

NASDAQ ACRS Coverage Bootstrap Healthcare Biotechnology Immunology

Latest ReportMay 13, 2026Aclaris Therapeutics: the three-shot catalyst stack racing the cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.